Head-to-head evidence
Tonlamarsen vs Zilebesiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Angiotensinogen (AGT) · full Hypertension pipeline
Tonlamarsen
Developed by Kardigan
NCT06864104 · Phase 2 · completed
The study randomized 206 participants to tonlamarsen or placebo with participants, care providers, investigators, and outcome assessors masked. Its primary outcomes were changes in plasma angiotensinogen. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT07511361 (registry estimate)
Zilebesiran
Developed by Alnylam Pharmaceuticals and partners
NCT04936035 · Phase 2 · completed
The study randomized 394 participants to placebo or zilebesiran and maintained quadruple blinding, with approximately 60–75 participants per treatment group analyzed for the primary endpoint. The primary clinical endpoint—change in 24-hour ambulatory systolic blood pressure at Month 3—was significantly favorable for zilebesiran versus placebo, supporting strong evidence from this trial.
Next expected readout: April 2028 · NCT07553442 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tonlamarsen's landscape · Zilebesiran's landscape